Consumer medicine information

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection

Potassium phosphate, monobasic; Potassium phosphate, dibasic

BRAND INFORMATION

Brand name

DBL Potassium Phosphate - Monobasic and Potassium Phosphate - Dibasic

Active ingredient

Potassium phosphate, monobasic; Potassium phosphate, dibasic

Schedule

Unscheduled

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection.

SUMMARY CMI

DBL™ Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I being treated with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection contains the active ingredients monobasic potassium phosphate and dibasic potassium phosphate. It is a mixture of simple phosphate salts used to quickly increase the amount of phosphate in your body. For more information, see Section 1. Why am I being treated with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection? in the full CMI.

2. What should I know before treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?

Do not use if you have ever had an allergic reaction to monobasic potassium phosphate or dibasic potassium phosphate or any of the ingredients listed at the end of the CMI. Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding. For more information, see Section 2. What should I know before treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How is DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection given?

  • This medicine is given as a slow injection into a vein. It must only be given by a doctor or nurse.
  • Your doctor will decide what dose you will receive and for how long you will need it. This depends on your medical condition and other factors, such as your weight.

More instructions can be found in Section 4. How is DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection given? in the full CMI.

5. What should I know during treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?

Things you should do
  • Tell any other doctors, dentists and pharmacists who treat you that you are being given DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection.
Looking after your medicine
  • This medicine will be stored in the pharmacy or on the ward.
  • Keep in a cool, dry place, where the temperature stays below 25°C.

For more information, see Section 5. What should I know during treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection? in the full CMI.

6. Are there any side effects?

Side effects include: swelling in the feet or lower legs, weight gain. Serious side effects include: increased thirst, muscle weakness, irregular heart beat, unexplained anxiety, weakness or heaviness in the hands or feet, tiredness or confusion, convulsions (fits) or muscle cramps, numbness or pain, breathing difficulties, tingling, prickling or burning sensations.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

DBL™ Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection

Active ingredient(s): monobasic potassium phosphate, dibasic potassium phosphate


Consumer Medicine Information (CMI)

This leaflet provides important information about DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about being treated with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection.

Where to find information in this leaflet:

1. Why am I being treated with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?
2. What should I know before treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?
3. What if I am taking other medicines?
4. How is DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection given?
5. What should I know during treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?
6. Are there any side effects?
7. Product details

1. Why am I being treated with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection contains the active ingredients monobasic potassium phosphate and dibasic potassium phosphate. It is a mixture of phosphate salts used to quickly increase the amount of phosphate in your body due to lower than normal levels of phosphate in your blood.

This medicine works by providing a source of phosphate for your body to use.

Your doctor may have prescribed this medicine for another reason.

Ask your doctor if you have any questions about why DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection has been prescribed for you.

2. What should I know before treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?

Warnings

Do not use DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection if you:

  • are allergic to monobasic potassium phosphate or dibasic potassium phosphate or any of the ingredients listed at the end of this leaflet. Symptoms of an allergic reaction may include:
    - shortness of breath, wheezing or difficulty breathing
    - swelling of the face, lips, tongue or other parts of the body
    - rash, itching or hives on the skin.
  • have any of the following medical conditions
    - kidney disease
    - Addison's disease
    - high blood levels of potassium or phosphate
    - low blood levels of calcium.

Check with your doctor if you:

  • have or have had any other medical conditions including:
    - kidney disease
    - pancreatic disease
    - parathyroid problems
    - muscle disease
    - rickets
    - electrolyte disturbances.
  • take any medicines for any other condition.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Your doctor will discuss the risks and benefits of using this medicine during pregnancy.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

Your doctor will discuss the risks and benefits of using this medicine during breastfeeding.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection and affect how it works. These include:

  • ACE inhibitors, medicines used to treat high blood pressure and some other heart conditions
  • medicines containing calcium, potassium or phosphate
  • cardiac glycosides such as digitalis
  • salicylates
  • non-steroidal anti-inflammatory drugs.

These medicines may be affected by DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection or may affect how well it works. You may need different amounts of our medicine, or you may need to take different medicines.

Your doctor or pharmacist has more information on medicines to be careful with or avoid while being given this medicine.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection.

4. How is DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection given?

How is it given

  • This medicine is given as a slow injection into a vein.
  • It must only be given by a doctor or nurse.

How much is given

  • Your doctor will decide what dose you will receive and for how long you will need it. This depends on your medical condition and other factors, such as your weight.

If too much is given (overdose)

As this medicine is given to you under the supervision of your doctor, it is very unlikely that you will receive too much.

If you think that you have been given too much DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection and you experience severe side effects, you may need urgent medical attention.

Symptoms of phosphate overdose include the side effects under Section 6. Are there any side effects? but are usually of a more severe nature.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know during treatment with DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection?

Things you should do

  • Tell any other doctors, dentists and pharmacists who treat you that you are being given DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection.
  • If you are going to have surgery, tell the surgeon or anaesthetist that you are being given this medicine. It may affect other medicines used during surgery.
  • If you are about to have any blood tests, tell your doctor that you are being given this medicine. It may interfere with the results of some tests.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection affects you.

Looking after your medicine

  • DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection will be stored in the pharmacy or on the ward.
  • Keep in a cool, dry place, where the temperature stays below 25°C.
  • Do not use this medicine after the expiry date.

Keep it where young children cannot reach it.

Getting rid of any unwanted medicine

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection will be disposed of by a nurse or pharmacist.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Common side effects

Common side effectsWhat to do
  • swelling in the feet or lower legs
  • weight gain
Speak to your doctor if you have any of these side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
  • increased thirst
  • muscle weakness
  • irregular heart beat
  • unexplained anxiety
  • weakness or heaviness in the hands or feet
  • tiredness or confusion
  • convulsions (fits) or muscle cramps
  • numbness or pain
  • breathing difficulties
  • tingling, prickling or burning sensations
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Do not be alarmed by this list of possible side effects. You may not experience any of them. Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

What DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection contains

Active ingredient
(main ingredient)
monobasic potassium phosphate
dibasic potassium phosphate
Other ingredients
(inactive ingredients)
water for injections

Do not take this medicine if you are allergic to any of these ingredients.

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection does not contain gluten, lactose, sucrose, tartrazine or any other azo dyes.

What DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection looks like

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection is a clear, colourless solution.

It is available in the following pack size:

  • 10 ampoules x 10 mL (AUST R 16268)

Each 10 mL ampoule contains:

  • monobasic potassium phosphate (540 milligrams)
  • dibasic potassium phosphate (1.83 grams)
  • water for injection.

Who distributes DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection

Pfizer Australia Pty Ltd
Sydney NSW
Toll Free Number: 1800 675 229
www.pfizer.com.au

This leaflet was prepared in September 2023.

Published by MIMS October 2023

BRAND INFORMATION

Brand name

DBL Potassium Phosphate - Monobasic and Potassium Phosphate - Dibasic

Active ingredient

Potassium phosphate, monobasic; Potassium phosphate, dibasic

Schedule

Unscheduled

 

1 Name of Medicine

Monobasic potassium phosphate.
Dibasic potassium phosphate.

2 Qualitative and Quantitative Composition

Each 10 mL ampoule contains 540 milligrams of potassium phosphate monobasic (KH2PO4) and 1.83 g of potassium phosphate dibasic (K2HPO4) in water for injection. The pH of the solution is approximately 7.5. Each mL of injection contains 2.5 mmol of potassium ions, 1.45 mmol of phosphate ions and 1.84 mmol of hydrogen ions.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection is a clear, colorless, sterile solution.

4 Clinical Particulars

4.1 Therapeutic Indications

Treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/L) and other degrees of hypophosphataemia when oral therapy is not possible.
The cause of hypophosphataemia should be identified and treated.

4.2 Dose and Method of Administration

Dosage.

For the treatment of severe hypophosphataemia, the following doses are suggested.

Adults.

Up to 10 mmol phosphate administered over 12 hours. The dose may be repeated at 12 hour intervals until serum phosphate exceeds 0.3 mmol/L.

Children.

0.15 to 0.33 mmol/kg administered over 6 hours. The dose may be repeated at 6 hour intervals until serum phosphate exceeds 0.6 mmol/L. The dose should not exceed the maximum recommended adult dose. The rate of infusion should not exceed 0.2 mmol/kg/hour.

Renal impairment.

Dose should be reduced. Use of phosphates in severe renal impairment is contraindicated (see Section 4.3 Contraindications).

Method of administration.

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection is administered by slow intravenous infusion.

Dilution.

DBL Potassium Dihydrogen Phosphate and Dipotassium Hydrogen Phosphate Concentrated Injection must be diluted before use. The drug can be given in 0.9% sodium chloride or 5% glucose solution. It should be administered by slow infusion to avoid phosphate intoxication.

Monitoring.

Serum sodium, potassium, phosphate and calcium concentrations and renal function should be monitored every 12 to 24 hours during therapy.
Conversion to oral phosphate therapy should occur as soon as possible.

4.3 Contraindications

Phosphate administration is contraindicated in patients with severe renal function impairment (less than 30% normal) since there is an increased risk of hyperphosphataemia in these patients.
Phosphate administration is contraindicated in patients with hyperphosphataemia, since phosphate therapy will exacerbate the condition.
Phosphate administration is contraindicated in patients with hypocalcaemia due to the close relationship between hypocalcaemia and hyperphosphataemia.
Potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection is contraindicated in patients with hyperkalaemia, since the potassium in the injection may exacerbate the condition.
Potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection is contraindicated in Addison's disease since there is an increased risk of hyperkalaemia in these patients.
Phosphate administration is contraindicated in urolithiasis (magnesium ammonium phosphate type, infected) since it may exacerbate the condition.

4.4 Special Warnings and Precautions for Use

Phosphate should be administered with caution in conditions where high phosphate levels may be encountered, such as hypoparathyroidism, chronic renal disease, and rhabdomyolysis.
Phosphate should be administered with caution in conditions where low calcium levels may be encountered, such as hypoparathyroidism, osteomalacia, chronic renal disease, acute pancreatitis, rhabdomyolysis and rickets.
Potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection should be administered with caution in conditions where high potassium levels may be encountered, such as acute dehydration, pancreatitis, rhabdomyolysis, severe renal insufficiency and extensive tissue damage (such as severe burns).
Potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection should be administered with caution in patients with myotonia congenita, and heart disease (particularly in digitalised patients), (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions), since these conditions may be exacerbated by the potassium in the injection.

Use in the elderly.

No data available.

Paediatric use.

No data available.

Effects on laboratory tests.

Saturation of bone binding sites by phosphate ions may cause decreased bone uptake of technetium Tc99m labelled contrast agents in bone imaging.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Angiotensin converting enzyme (ACE) inhibitors.

Concurrent use with potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection may result in hyperkalaemia, especially in patients with renal impairment.

Calcium containing medicines.

Concurrent use of phosphate and calcium containing medicines may increase the risk of deposition of calcium in soft tissues.

Digitalis glycosides.

The administration of potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection in digitalised patients with severe or complete heart block may result in hyperkalaemia.

Diuretics, potassium sparing.

Concurrent use with potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection may result in hyperkalaemia, especially in patients with renal impairment.

Non-steroidal anti-inflammatory agents (NSAIDs).

Concurrent use with potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection may result in hyperkalaemia, especially in patients with renal impairment.

Other phosphate containing medicines.

Concurrent use with potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection may result in hyperphosphataemia, especially in patients with impaired renal function.

Potassium containing medicines.

Concurrent use with potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection may result in hyperkalaemia, especially in patients with renal impairment.

Salicylates.

Concurrent use with potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection may increase the serum concentration of salicylates, since salicylate excretion is decreased in acidified urine. This may result in toxic salicylate concentrations when phosphate is administered to patients already stabilized on salicylates.
For information regarding physicochemical incompatibilities please, see Section 6.2 Incompatibilities.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
Animal reproduction studies have not been conducted with this product. It is not known whether this product can adversely affect the foetus when administered to a pregnant woman. Therefore, potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection is not recommended for use during pregnancy.
It is not known whether phosphates are excreted into breast milk, therefore potassium dihydrogen phosphate and dipotassium hydrogen phosphate concentrated injection is not recommended for use during lactation.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Cardiovascular.

Uncommon: hypotension. Rare: myocardial infarction.

Endocrine/metabolic.

The following events have been reported but are uncommon.
Fluid retention as indicated by swelling of feet or lower legs or weight gain.
Hyperkalaemia leading to confusion, tiredness or weakness, irregular or slow heart rate, numbness or tingling around lips, hands or feet, unexplained anxiety, weakness or heaviness of legs, shortness of breath or troubled breathing.
Hypernatraemia leading to confusion, tiredness or weakness, convulsions, oliguria or decreased frequency of micturition, tachycardia, headache or dizziness, increased thirst.
Hyperphosphataemia, hypocalcaemia or hypomagnesaemia leading to convulsions, muscle cramps, numbness, tingling, pain or weakness in hands or feet, shortness of breath or troubled breathing, tremor.
Extraskeletal calcification as nephrocalcinosis has been reported in children with hypophosphataemic rickets treated with phosphate supplements.

Genitourinary.

Rare: acute renal failure.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Clinical features.

Hyperphosphataemia may occur when large doses of phosphate are given, especially in patients with renal failure. Symptoms associated with hyperphosphataemia include muscle weakness, paraesthesia, muscle cramps, convulsions, cardiomyopathy, respiratory failure and haematological abnormalities.
Hyperphosphataemia may in turn lead to hypocalcaemia and to ectopic calcification, which may be severe.
Crystal deposition may occur in important structures including blood vessels of the eye, lung, heart and kidney. Fatal alveolar diffusion block has occurred, the risk being greater if the patient is alkalotic.

Treatment.

Treatment of overdosage involves the following measures:
immediate cessation of phosphate therapy;
correction of serum electrolyte concentrations, especially calcium;
general supportive treatment.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

The majority (80%) of the body's phosphate is found as calcium phosphate in the skeleton, where it gives rigidity to the bone. The remainder is found in soft tissues. Phosphate is the principle anion of intracellular fluid. In body fluids, phosphate is present mainly as divalent hydrogen phosphate (HPO42-) ions (approximately 80%) and monovalent dihydrogen phosphate (H2PO4-) ions (approximately 20%).
Apart from its essential role in bone structure, phosphate is also important in many metabolic and enzymatic pathways. It is involved in energy storage and transfer, the utilization of B-complex vitamins, the buffering of body fluids, and in the renal excretion of hydrogen ions.
Hypophosphataemia may arise from a variety of causes including primary hyperparathyroidism, vitamin D deficiency, X-linked familial hypophosphataemia, alcoholism, hepatic failure and septicaemia. The symptoms of hypophosphataemia include muscle weakness, paraesthesia, convulsions, cardiomyopathy, respiratory failure and haematological abnormalities. Prolonged hypophosphataemia may result in rickets or osteomalacia.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

The normal concentration range of phosphate in plasma is 0.8 to 1.5 mmol/L.
Phosphate is primarily excreted in the urine. Over 90% of plasma phosphate is filtered in the kidneys with the majority being reabsorbed in the proximal tubule. Parathyroid hormone decreases the tubular reabsorption of phosphate, thereby increasing urinary excretion. In addition, serum phosphate levels are inversely related to serum calcium levels and to renal metabolism of vitamin D. A decrease in serum calcium concentration will result in increased serum phosphate levels.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Water for injections.

6.2 Incompatibilities

Phosphates are reported to be incompatible with calcium or magnesium containing solutions.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C.

6.5 Nature and Contents of Container

Ampoule containing a clear colourless solution. See Table 1.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Potassium phosphate dibasic is a colourless or white, hygroscopic granular powder. It is freely or very soluble in water and very slightly soluble in alcohol. Potassium phosphate monobasic is a white, odourless, granular or crystalline powder, or colourless crystals. It is freely soluble in water and practically insoluble in alcohol.

Chemical structure.

The molecular formula of potassium phosphate dibasic is K2HPO4, and of potassium phosphate monobasic is KH2PO4. The molecular weight of potassium phosphate dibasic is 174.2, and of potassium phosphate monobasic is 136.1.

CAS number.

The CAS Registry number of potassium phosphate dibasic is 7758-11-4, and of potassium phosphate monobasic is 7778-77-0.

7 Medicine Schedule (Poisons Standard)

Not scheduled.

Summary Table of Changes